TCGA-P3-A5QA-01A-11R-A28V-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.640
- ANGIOGENESIS+0.500
- MYOGENESIS+0.360
- PANCREAS_BETA_CELLS+0.350
- UV_RESPONSE_DN+0.330
- TNFA_SIGNALING_VIA_NFKB+0.300
- HYPOXIA+0.290
- TGF_BETA_SIGNALING+0.280
- PROTEIN_SECRETION+0.210
- COAGULATION+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.470
- INTERFERON_GAMMA_RESPONSE-0.330
- PEROXISOME-0.330
- MYC_TARGETS_V2-0.320
- ALLOGRAFT_REJECTION-0.310
- OXIDATIVE_PHOSPHORYLATION-0.310
- FATTY_ACID_METABOLISM-0.280
- HEME_METABOLISM-0.250
- ESTROGEN_RESPONSE_LATE-0.230
- ADIPOGENESIS-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613779 | — | D | 0.844 |
| 2 | TCGA-P3-A6T8-01A-11R-A34R-07 | — | — | 0.830 |
| 3 | SNU182_LIVER | HCC | — | 0.812 |
| 4 | SRR25043621 | — | — | 0.812 |
| 5 | TCGA-HD-7831-01A-11R-2132-07 | — | — | 0.798 |
| 6 | TCGA-IQ-A61O-01A-11R-A30B-07 | — | — | 0.782 |
| 7 | TCGA-CN-6022-01A-21R-1686-07 | — | — | 0.780 |
| 8 | TCGA-UF-A7JD-01A-11R-A34R-07 | — | — | 0.775 |
| 9 | TCGA-BA-6868-01B-12R-1915-07 | — | — | 0.775 |
| 10 | TCGA-D8-A27H-01A-11R-A16F-07 | — | E | 0.771 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.640 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.080 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.060 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.030 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.030 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.020 | Inavolisib | — uncovered |